Evidence map›Paper›PMID 42292793›Full record

ReviewFrontiers in pharmacology2026

Cell type-specific pharmacological modulation of the neuro-immune axis: the role of ADRB2 signaling in reshaping the tumor ecosystem.

Wenjun Meng, Mengting Li, Ruoyu Ren, Xiaoli Mu, Bin Hou, Qing Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenjun Meng *Department of Pain Management, West China Hospital, Sichuan University, Chengdu, China.
Mengting Li *Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Ruoyu RenWest China School of Medicine, Sichuan University, Chengdu, China.
Xiaoli MuHealth Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China.
Bin HouDepartment of Rehabilitation Medicine, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
Qing LiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenergic signaling through β2-adrenergic receptor (ADRB2) is a conserved neuro-immune axis that modulates tumor biology at multiple levels: tumor cells, stromal compartments (CAF, endothelium), myeloid populations (MDSC/TAM), and lymphocytes (CD4

Indexed as

ADRB2cell type-specific targetingimmune modulationneuro-immune axistumor microenvironmentβ-adrenergic signalingβ-blocker

Identifiers

PMID42292793
PMCPMC13253736

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.